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Objective:  The  objective  of this  study  is  to identify  the  possible  barriers  and  critical  success
factors  for  the  implementation  of  European  collaboration  in  the  ﬁeld  of  relative  effective-
ness  assessment  (REA)  of drugs.
Methods:  Data were  gathered  through  semi-structured  interviews  with  representatives
from  eight  European  health  technology  assessment  (HTA)  organisations  involved  in  assess-
ment  of  drugs  for  coverage  decision-making  (AAZ,  AIFA,  AHTAPol,  HAS,  HVB,  IQWIG,  NICE
and ZiN).
Results:  Potential  barriers  identiﬁed  mainly  relate  to  methodology,  resources  and  chal-
lenges with  implementation  in  the  respective  national  processes  (e.g.  legal  restrictions).
The  most  critical  success  factors  for production  of  cross-border  assessments  were  the  con-eimbursement tinuous  cooperation  of competent  partners,  and  the  quality  and  timely  availability  of the
assessment.
Conclusion:  Further  adaptation  of  the  process  and methods  is required  for optimal  col-
laboration.  In  the  near  future it can  be expected  that  cross-border  assessments  will
meet  in  particular  the  needs  of  smaller/middle-sized  European  countries  and  also  Euro-
pean countries  with  less  developed  HTA  systems  as the  potential  efﬁciency/quality  gains
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are  the highest  for these  countries.  Therefore,  national  implementation  of cross-border
assessments  is especially  likely in these  countries  in  the  coming  years.  Once  more  expe-
rience  is gained  with  cross-border  assessments,  and  successes  become  more  evident,
efﬁciency/quality  gains  may  also  be  likely  for some  larger  countries  with well  established
processes.
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1. Introduction
Insurance entities in many nations use health technol-
ogy assessments (HTA) to prioritise drugs for reimburse-
ment [1]. European countries employ different analytical
frameworks to guide their assessments of drugs as part
of the coverage decision making process [2]. Most assess-
ments include a variety of criteria, of which clinical
effectiveness and safety relative to the comparator (also
referred to as relative or comparative effectiveness) are the
most widely used. Examples of other relevant criteria are
cost-effectiveness, budget impact, drug/innovative char-
acteristics, availability of therapeutic alternatives, equity
considerations, public health impact and research and
development [2].
Although coverage decisions for drugs in Europe are
mostly made at a national or regional level and may  dif-
fer between countries, this does not preclude member
states from sharing the scientiﬁc assessments on which
their decisions are based [3]. Increased European collabora-
tion and harmonisation in the ﬁeld of relative effectiveness
assessment (REA)/health technology assessment (HTA)
may  save resources and prevent duplication of work for
both manufacturers and coverage decision agencies [2–4].
However, it could also carry the risks of losing local con-
textualisation, of the application of standards that are not
universally accepted and slowing the rate of development
and innovation in the analytical disciplines supporting the
assessments [3].
In 2005, the European Commission established that a
REA, a speciﬁc element of HTA, is a relevant tool to iden-
tify the most valuable drugs, and allow containment of
drug costs as well as a fair reward for innovation. The
Commission set up a Working Group on Relative Effec-
tiveness as part of the High Level Pharmaceutical Forum
(2006–2008, see Fig. 1) with the aim to support Member
States in applying REAs. The High Level Pharmaceutical
Forum consisted of Ministries of the Member States as
well as relevant stakeholders. In 2008, the High Level
Pharmaceutical Forum endorsed the deﬁnition of relative
effectiveness as: the extent to which an intervention does
more good than harm compared to one or more intervention
alternatives for achieving the desired results when provided
under the usual circumstances of health care practice [5]. As
this deﬁnition includes harms, the concept is similar to
what in many countries is referred to as the net therapeu-
tic beneﬁt or relative therapeutic value. This is conﬁrmed
by the statement of the High Level Pharmaceutical Forum
that the aim of REA is to compare healthcare interventions in
daily practice and classifying them according to their added
therapeutic value.ished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under
D  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The work of the High Level Pharmaceutical Forum
on REA was  continued by the European network for
Health Technology Assessment (EUnetHTA) (see Fig. 1).
Between 2010 and 2012, work package 5 of EUnetHTA
Joint Action 1 (WP5/JA1), developed several products and
tools that aim to facilitate collaboration in this ﬁeld [6].
Most important were a structure for jointly producing
and reporting scientiﬁc relative effectiveness information
for trans-national use (HTA Core Model® for Rapid Rel-
ative Effectiveness Assessment of Pharmaceuticals) and
methodological guidelines on issues relevant to REAs. The
development of the HTA Core Model® for Rapid REA of
Pharmaceuticals was  based on the work of EUnetHTA on
the original HTA Core Model® [7] but adapted to suit
the expectation and requirements of rapid REAs of drugs
[6]. The nine methodological guidelines focus on issues
that assessors are frequently challenged with: endpoints
(clinical endpoints, composite endpoints, surrogate end-
points, safety and quality of life), comparisons (choice of
appropriate comparator and direct and indirect compar-
isons) and level of evidence (internal validity of randomised
controlled trials and applicability) [8]. Both Model and
Guidelines were tested by a pilot assessment of the drug
pazopanib for renal cell carcinoma [9]. Currently, the Model
and Guidelines are being further piloted as part of WP5
Joint Action 2 (WP5/JA2, 2012–2015) [10,11].
As European countries have different healthcare sys-
tems with their own dynamics, they may  have different
challenges for collaboration in the ﬁeld of REA. Litera-
ture data on challenges, barriers and factors facilitating
international collaboration on cross-border HTAs is scarce
[12–14]. Recently Huic´ et al. [14] concluded that timely
and efﬁcient collaborative HTA processes on relative efﬁ-
cacy/effectiveness and safety on different types of health
technologies are possible in Europe but there are still bar-
riers to overcome.
In order to maximise the likelihood of successful col-
laboration in the ﬁeld of REA, we wanted to research the
challenges and success factors on collaboration in more
detail. Therefore, the objective of this study is to identify the
possible barriers and critical success factors for the imple-
mentation of European collaboration in the ﬁeld of REA of
drugs.
2. Methods
2.1. Study design and periodwhich eight interviews were performed between 8th and
16th January 2013.
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Fig. 1. European collaboration on relative effectiveness assessment of drugs. The historical context of collaboration in the ﬁeld of relative effectiveness
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wssessment of drugs in Europe.
A cross-border assessment of relative effectiveness of
harmaceuticals in Europe was deﬁned as an assessment
f pharmaceuticals reported and co-produced by at least
wo countries. Preferably, more countries (ﬁve) should be
nvolved in reviewing the report. The results of the assess-
ent (or parts of them) can then be available to be used by
other) European countries in their national assessment.
.2. Participants
Data were gathered through semi-structured inter-
iews with representatives from eight European HTA
rganisations involved in the assessment of drugs for cov-
rage decision making, which participated in WP5/JA1. The
epresentatives were nominated for the interviews by the
TA organisations participating in WP5/JA1. For this study
 limited number of HTA organisations were chosen (eight)
s it was not possible to interview all organisations within
he available timeframe. In addition, it was assumed that
ased on the selection of organisations sufﬁcient diversity
n opinions was guaranteed for this study. The selection
f the organisations was based on including the four most
opulous European jurisdictions (France, Germany, Italy
nd England), two middle-sized countries (Austria and the
etherlands) and two central/eastern European countries
Poland and Croatia). The representatives of HTA organisa-
ions were contacted by email. All respondents approached
articipated in the study. The organisations are presented
n Table 1.
.3. Survey instrument and data collection
A standardised data extraction form (questionnaire)
as developed with input from WP5/JA1 members. The
orm included a total of 23 questions (see Supplement 1)
ivided in three parts. The 1st part was focused on expec-
ations from European collaboration in the ﬁeld of REA
Q1–Q3); the 2nd part on potential challenges for Euro-
ean collaboration in the ﬁeld of REA (Q4–Q18) and the 3rd
art on critical success factors for cross-border assessments
Q19–Q23).The questionnaire was sent to the interviewees in
dvance. Data were captured via a 1-h telephone inter-
iew. The interviews were not recorded. All interviews
ere conducted by W.T. (PharmD) experienced in coverageassessments of drugs. The average age of the interviewees
at the time of the interviews was  50 and 3/8 (38%) were
male.
2.4. Data analysis
The results were processed as qualitative information.
The results of the interviews were handled conﬁdentially.
The answers were checked by a second researcher for
inconsistencies and clarity. In case of inconsistencies/lack
of clarity a follow-up contact with the respondent was
established asking for further explanation. The results
were aggregated into a summary. In order to guarantee
anonymous presentation of the data, the exact number of
countries giving a speciﬁc response is not presented, unless
all countries agreed. Anonymous participant quotations are
presented to illustrate the themes. The summary was sent
to the respondents for validation. Input received as a result
of the validation was processed accordingly.
The COREQ check-list, a 32-item checklist for explicit
and comprehensive reporting of qualitative studies, was
used for reporting the methods section [15].
3. Results
3.1. Expectations from European collaboration in the
ﬁeld of REA
3.1.1. Extent of collaboration
Collaboration (in the broadest sense, from exchange of
information to cross-border production of assessments)
between European Union (EU) member states on REAs was
seen as a positive development.
The respondents agreed that member states should ﬁrst
focus on collaboration in the ﬁeld of relative effective-
ness, before addressing health economic issues. Several
respondents indicated that they think there are less dif-
ferences in REAs between EU countries and regions within
countries (= to be referred to as countries) compared
with economic assessments. Opinions differed regarding
the desired extent of the cooperation. Some respondents
were in favour of cross-border production of assessments
that can be used directly in the national decision-making
process. Others were more reserved and would like to
limit the collaboration to exchange of information and/or
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Table 1
Jurisdictions and organisations included in the study.
Jurisdiction Assessment Agency
Austria Hauptverband der Österreichischen Sozialversicherungsträger (HVB)
Croatia Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi (AAZ)
France Haute Autorité de Santé (HAS)
Germany Institut für Qualität und Wirtschaftlichkeit im Gesundheidswesen (IQWIG)
Italy  Agenzia Italiana del Farmaco (AIFA)
Netherlands Zorginstituut Nederland (former CVZ)
dycznyc
d ClinicPoland Agencja Oceny Technologii Me
England National Institute for Health an
methodology development. A mandatory cross-border
production of assessments was not preferred by any of the
respondents.
3.1.2. Inﬂuence of cross-border assessments on national
autonomy and expertise
Most respondents considered coverage in healthcare
to be a politically sensitive issue as it is expected that
no country would be willing to give up its autonomy
in decision-making. However, it was also indicated that
the sensitive aspects are less likely to be in the technical
domains of a REA but more likely to be caused by economic,
societal and nationally speciﬁc elements. Therefore, most
respondents agreed that the production of cross-border
REAs does not conﬂict with the principle of subsidiarity.
The subsidiarity principle is deﬁned in Article 5 of the
Treaty on EU and in this case refers to the principle that
decision making regarding healthcare and social security
is a national competence in EU Member States.
It was indicated by some respondents that if (part of) a
cross-border assessment would be included in the national
procedure, this would inﬂuence the autonomy of the HTA
organisation to some extent as it would be difﬁcult to
explain an interpretation of relative effectiveness which is
different to the one presented in the cross-border assess-
ment. This would at least require a transparent explanation.
All respondents agreed that cross-border collabora-
tion would lead to an increase in national expertise by
sharing insights and information. It was indicated that fre-
quent personal contacts between staff from different HTA
organisations (e.g. international meetings, internships) are
relevant to build trust. None of the respondents expected
a reduction in the number of staff needed for the national
process.
3.1.3. Inﬂuence of cross-border assessments on the time
to market
Most respondents considered it unlikely that a cross-
border assessment will lead to a decrease in the time to
market of new drugs since a national process will still
be needed and the REA is only a part of the coverage
decision making process. It was mentioned by some that
cross-border REAs initially may  slow down the process
in countries with an already well established procedure,
thereby negatively inﬂuencing the average duration of time
to market. On the other hand, in countries that have just
started with such assessments it is to be expected thath (AHTAPol)
al Excellence (NICE)
cross-border assessments could lead to a faster assessment
and thereby speed up the national decision making.
Two  respondents pointed out that cross-border assess-
ments of new drugs may  result in freeing up of more
resources on a national level for activities such as spend-
ing time on exploring social/ethical values or (re)assessing
drugs that are already reimbursed.
3.1.4. Inﬂuence of cross-border assessments on the
quality of decision making
Most respondents felt the general quality level of deci-
sion making among European countries would be raised by
cross-border assessments, although maybe not compared
with the present level in some individual countries. A small
majority of the respondents expected that the transparency
in decision making may  increase to some degree. It was
indicated by one respondent that making both the submis-
sion dossier of the marketing authorisation holder as well
as the ﬁnal assessment publicly available would probably
lead to the highest transparency.
3.2. Potential challenges for European collaboration in
the ﬁeld of REA
3.2.1. Potential challenges for the uptake of the HTA Core
Model and/or Guidelines for Rapid REA of
Pharmaceuticals in the national setting
There were diverging opinions regarding potential
problems for implementing the HTA Core Model and/or
Guidelines for Rapid REA of Pharmaceuticals in the national
setting. Whereas some respondents did not foresee any
problems, others identiﬁed several challenges. The poten-
tial challenges that were mentioned by respondents are
listed in Table 2.
We identiﬁed nine key potential challenges. A number
of the challenges identiﬁed refer to potential differences
between the national way of working and EUnetHTA
Model and Guidelines regarding content and the use of
more or less advanced methodology, and how strictly or
pragmatically methodologies are applied. One example of
differences in content was  that in some countries unpub-
lished data from the registration-dossier can be included
in the dossier, while in other countries unpublished data
are not accepted. Another respondent indicated that there
is too much emphasis on safety which may  duplicate
information from EMA. A further example was  that effec-
tiveness is not evaluated separately in every country, as in
some countries it is integrated into the cost-effectiveness
S. Kleijnen et al. / Health Policy 119 (2015) 569–576 573
Table  2
Potential challenges for uptake of the HTA Core Model and/or Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals in national setting.
• National assessments may  not have the same content as assessments produced with the Model/Guidelines
•  In national assessments methodologies may  not be applied as strictly or pragmatically as in assessments produced with the Model/Guidelines (e.g.
use  of surrogate endpoints)
• For national assessments less/more advanced methodology may be used (e.g. use of indirect comparisons)
•  The resources associated with having to adapt the Model’s outcomes to the national procedure
•  Implementation may  lead to longer timelines which is a problem as the assessment of new drugs has to be done in a timely manner
•  Implementation may  lead to loss of autonomy in deciding on the outcome of the relative effectiveness assessment.
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i•  Legal restrictions that hinder the use of the Model/Guidelines (e.g. use
•  There may  be variance in the interpretation of the methods in the Mo
•  It is questioned whether the Model is suitable for submission based a
valuation. An example of different attitudes to the
trictness with which to apply methodologies that was
entioned was  the divergence in acceptance of surrogate
utcomes.
Further, it was indicated that the time and resources
ssociated with having to adapt the Model’s outcomes to
he national procedure may  be an issue. This may  be due
o differences in content or because for some countries a
ranslation of an assessment produced with the Model is
equired for national implementation. It was also pointed
ut by one respondent that the current format of assess-
ents produced with the Model is not very suitable for
onsultation or decision making due to its repetitive and
engthy nature.
.2.2. Potential challenges for the production of
ross-border assessments
.2.2.1. Methodological challenges. The most frequently
entioned methodological problem for the production of a
ross-border assessment was the choice of the comparator.
t was indicated that the principles for choosing the com-
arator(s) can vary between countries. For instance, not all
ountries include drugs used off label or best supportive
are as a comparator. It was also indicated that the process
or choosing the right comparator may  differ (e.g. based
n the proposal of the manufacturer or on input from a
ational physician organisation).
Another methodological challenge mentioned was  the
ifference between countries in accepting indirect com-
arisons, if direct evidence is lacking. Further, it was
oticed that countries may  differ in the acceptance of
ntermediate or surrogate endpoints (e.g. glycosylated
aemoglobin values versus outcomes on microvascular and
acrovascular complications in diabetes patients). Finally,
t was indicated that some countries prefer evidence from
andomised clinical trials whereas other countries also
onsider observational studies.
.2.2.2. Process, time constraints and resources. Almost all
espondents indicated that the work on a cross-border
ssessment has to start very early in order for the results
o be available in time for national decision making. Some
espondents even indicated that they may  prefer to start
he national procedure along with the cross-border assess-
ents due to limited timelines.
It was also mentioned that resources and time are
eeded to achieve consensus between countries, for exam-
le on which comparators/studies/outcomes should be
ncluded. In addition, it was estimated that broadening theublished data or inclusions off-label treatments)
een assessors and/or countries
nts (e.g. more suitable for ‘de novo’ assessments)
scope to meet multiple demands could lead to additional
pressure on the already limited time and resources avail-
able.
Finally, it was mentioned that it may  cost extra
resources to have staff that can write reports in English.
3.3. Critical success factors for cross-border assessments
A total of 14 critical success factors for the cross-border
assessments were identiﬁed by the respondents. They are
listed in Table 3.
The success factors in general refer to either political
aspects, building trust between countries, the quality of
the assessments or the process and its management. It
was clear from the interviews that a high quality assess-
ment is expected which should be adaptable to the national
situation. The report should be transparent, have a clear
structure and be both comprehensive and succinct. In addi-
tion it was  mentioned that there should be agreement on
methodology, but also enough room to meet demands of
individual countries.
Respondents emphasised that differences in method-
ological approaches may  be solved by identifying them
at an early stage. For instance, it was mentioned that
the potential challenge of different comparators can be
solved by including multiple (indirect) comparisons in the
assessment. Further, it was emphasised that a signiﬁcant
part of the scoping-process should be done long before
the marketing authorisation date, e.g. identifying stake-
holders to be consulted, choice of comparators, outcomes
and the population. It was also emphasised that in this
case, the risk that an application for regulatory registra-
tion could be rejected or withdrawn should be taken into
account.
Several respondents indicated that a cross-border
report should be produced by at least two countries, acting
as author and co-author. Further, to enhance the quality, it
was suggested that a number of additional reviewers would
be desirable, ranging from a couple to all countries that
agreed to use the assessment. It was indicated that in order
to make the project a success, the steady cooperation of at
least ﬁve to seven countries is probably needed.
3.3.1. Added value to national reports and other
important factorsMost respondents saw some opportunities for adding
useful elements to their national reports by using a
cross-border assessment. The following were mentioned:
a standardised literature search, extensive background
574 S. Kleijnen et al. / Health Policy 119 (2015) 569–576
Table 3
Critical success factors for cross-border assessments.
• Willingness to cooperate and high degree of commitment by different countries
•  Voluntary use of the assessment
•  Investment in personal contacts for building trust between participating countries
•  Competent, independent, qualiﬁed assessment teams in the participating countries
•  Transparent process and output
• Clear and comprehensive structure of the report
• High quality of the assessment which should be transferable to the national situation
•  Common understanding and agreement on methodology, but with enough room to meet demands of individual countries as well
•  Efﬁcient project management at the European level
•  Timely communication of relevant information about the planned assessment to national organisations so they plan their national assessment
accordingly
•  Early agreement on scope and participating countries
•  Need for a clear and effective topic selection process that is relevant for the majority of countries
•  Report production by an authoring country, a co-authoring country and involvement of several countries in reviewing the assessment
•  Cooperation with stakeholders with involvement of
n the dr
•  manufacturers for submitting a dossier
•  manufacturers, doctors and patients for scoping and commenting o
information, multiple comparisons, information about cov-
erage decisions/recommendations in other countries, a
reﬁnement of categories of added therapeutic value, orga-
nisational and ethical aspects and modelling (e.g. indirect
comparisons). One respondent also indicated that it would
be desirable to have information on the prices and (hope-
fully) risk-sharing schemes in other countries, although
this was also mentioned to be unlikely due to conﬁdential-
ity issues. Further it was mentioned that a re-evaluation
after three years would be appreciated.
The respondents mentioned that the length of the report
is of less importance, although preferably it should be
comprehensive but succinct. Some recommended that the
technical data could be included as an appendix.
4. Discussion
Whereas several studies have analysed and discussed
differences and similarities between countries in criteria,
methods or outcomes of coverage assessments of drugs
[2,16–20], the potential for harmonisation/collaboration
between countries has only been studied by a few
[3,4,14,21]. Kleijnen et al. [4] studied the similarities and
differences in the assessment of relative effectiveness in
29 jurisdictions. The authors concluded that some impor-
tant methodological aspects of REA are approached in a
similar way in many jurisdictions, indicating that collabo-
ration on assessments may  be feasible. This study adds to
the evidence base by identifying actual barriers and success
factors for collaboration between countries in the ﬁeld of
REA of drugs.
Our study found that there is willingness to cooper-
ate in the development and standardisation of methods
for relative effectiveness in Europe and that it is expected
to lead to an increase of quality and expertise throughout
Europe. However, the desired extent of the collabora-
tion varies between countries. Potential barriers identiﬁed
mainly relate to methodology, resources and challenges
with implementation in the national process (e.g. legal
restrictions). The most critical success factors for pro-
duction of cross-border assessments were the continuous
cooperation of competent partners, and the quality and
timely availability of the assessment.aft report
The results of this study conﬁrm some of the ﬁndings
of Hutton et al. [3]. The results conﬁrm that harmonisation
of HTA across jurisdictions should not, and cannot, aim to
produce a single decision on coverage and utilisation of a
technology. However, harmonisation and/or collaboration
are more likely on the evaluation of clinical evidence.
Moreover, the results conﬁrm the conclusion from Huic´
et al. [14] that the smaller/middle-sized countries and also
countries that have less developed HTA systems show the
highest willingness to conduct cross-border assessments.
This may  relate to the fact that these countries will proﬁt
most from efﬁciency gains from cross-border assessments.
In countries with a well embedded and legalised structure
it may  be more difﬁcult to adopt methods used in other
counties or change the process compared with countries
with a less well-developed system. Further, the willing-
ness of an individual country to collaborate will be highly
dependent on whether or not it can use the resulting report
in the national setting (whether the report fulﬁls the spe-
ciﬁc needs and demands). For example, different compara-
tors were included by Germany and England in their assess-
ment of ticagrelor for the treatment of acute coronary syn-
drome as legal requirements stipulate that in Germany the
comparator has to be licensed for the indication, whereas
in England also ‘off-label’ comparators are accepted [22].
At this time point, there is some doubt whether a cross-
border assessment may  lead to a decrease in the time to
market of new drugs in Europe as a cross-border assess-
ment would not replace the subsequent national process.
The assessment has to be integrated in the national process
along with other evidence (such as on cost-effectiveness),
legal considerations and social values. Further streamlin-
ing of national processes and cross-border assessments
could reduce the total time needed. Naturally, a shorter
time to the market would be of beneﬁt to manufactur-
ers and patients. However, it is not clear yet whether this
can be established in the short run. A potential beneﬁt for
manufacturers that is more realistic in the next years may
be a reduction of resources because of less duplication of
information. Manufacturers spend considerable resources
in preparing jurisdiction-speciﬁc submission ﬁles. There-
fore, the use of the (same) REA part of the submission ﬁle
in several jurisdictions may  lead to efﬁciency gains.
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Our study shows that some issues need to be worked out
n more detail in order to increase European collaboration
n the ﬁeld of REAs of new drugs. Therefore it is essential
hat the following recommendations should be taken into
ccount for future cross-border assessment:
 The cross-border assessments should not limit the time
available for the national assessments and decision mak-
ing. In order for the cross-border assessment to be
available in a timely fashion, the scoping should start in a
very early stage, preferably before the marketing autho-
risation, including identiﬁcation of relevant stakeholders
that should be included in the process. The risk that an
application for marketing authorisation could be rejected
or withdrawn should be accounted for.
 The selection of the topics (drugs to be assessed) and the
countries participating in the cross-border assessment
should be transparent.
 The scoping process should identify the needs of the
different countries, especially regarding multiple com-
parators, direct and indirect comparisons, the use of
both intermediate and ﬁnal endpoints (patient-relevant
and clinically signiﬁcant endpoints), and the analysis of
relevant subgroups. The goal should be to offer an opti-
mum  number of analyses to meet the needs of as many
countries as possible, but with careful consideration of
relevance, workload and time constraints.
 Each country should be able to select that part of the
assessment which is relevant to its national context and it
should be easy to tailor those parts towards the national
needs. Therefore a common understanding and agree-
ment on methods needs to be developed with sufﬁcient
room for variation to meet as many individual demands
as possible. The structure of the report should be clear and
comprehensive and the use of the assessment should be
voluntary.
 For producing a cross-border report, by deﬁnition at least
two countries must be involved, acting as author and
co-author. But to raise the quality, a number of addi-
tional reviewers is desirable, ranging from a couple to all
countries that agreed to use the assessment. In order to
make cross-border assessments a success in the long run,
the steady cooperation of at least ﬁve to seven countries is
probably desirable. Efﬁcient project management at the
European level is needed.
 Optimal transparency of decision criteria is needed to
explain potential different outcomes of the coverage pro-
cess in the individual countries. It should be actively
communicated that the legal frameworks and the pur-
chasing power of EU countries vary considerably and that
therefore different decisions in the member states are
possible.
Our study has some limitations. This study included a
imited set of HTA organisations as it was not possible to
nterview all European organisations within the available
imeframe. Therefore the identiﬁed potential barriers and
uccess factors may  not be exhaustive. However, ﬁve out of
ight organisations were from large countries. As argued
efore, large countries may  be more reluctant towards
ollaboration resulting in a critical panel for the study. 119 (2015) 569–576 575
Therefore, the results of this study may  present a relatively
critical attitude compared with the European average, but
it is also likely that the majority of the potential barriers
are identiﬁed. In addition, it was  assumed that based on
the selection of organisations sufﬁcient diversity in opin-
ions was guaranteed for this study. Finally, the differences
in the terminology used in different countries may  have
affected the accuracy of some data. Further research that
would include a wider set of HTA organisations from small,
middle-sized and Central/Eastern European countries
would be helpful for conﬁrming the current ﬁndings.
In conclusion, there is willingness to cooperate in the
development and standardisation of methods for REAs
in Europe. However the desired extent of the collabora-
tion varies between countries. In the near future it can
be expected that cross-border assessments will meet in
particular the needs of smaller/middle-sized European
countries and also European countries with less developed
HTA systems as the potential efﬁciency/quality gains are
the highest for these countries. Therefore, national imple-
mentation of cross-border assessments is especially likely
in these countries in the coming years. Further adapta-
tion of the process and methods is required for optimal
collaboration. Once more experience is gained with cross-
border assessments, and successes become more evident,
efﬁciency/quality gains may  also be likely for some larger
countries with well established processes.
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